A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)MedDRA version: 8.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB
- Registration Number
- EUCTR2006-005122-23-LV
- Lead Sponsor
- Merck & Co., Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 1000
1.Patient has a histologically- or cytologically-confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC
2. Patient has received no prior systemic chemotherapy, with the exception of adjuvant chemotherapy for NSCLC. If the patient has received prior adjuvant chemotherapy for NSCLC, it must have been completed 12 months or more prior to study enrollment
3. Patient is =18 years of age; has measurable disease as defined by at least 3 weeks from any prior major surgery or radiation therapy and has adequately recovered from the toxicity and/or complications of these interventions
4.Patient has Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1; adequate organ function.
5.Female patient of childbearing potential has a negative pregnancy test (serum) within 72 days of study enrollment.
6.Patient agrees to: (1) use 2 adequate methods of contraception to prevent pregnancy (either 2 barrier methods or a barrier method plus a hormonal contraceptive method)or (2) abstain from heterosexual activity throughout the study starting with Visit 1
7.Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.
8.Patient or patient’s legal representative has voluntarily agreed to participate by giving written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1.Patient has been treated with any investigational agent for any indication within 4 weeks of study enrollment.
2.Patient has an active infection or has received intravenous antibacterial, antiviral, or antifungal medications within 2 weeks prior to enrollment.
3.Patient has a prior history of treatment with HDAC inhibitors. Patients who have received valproic acid (VPA) for the treatment of seizures may be enrolled on this study, but must not have received VPA within 30 days of study enrollment.
4.Patient is on any systemic steroids for any indication, with doses that have not been stabilized to the equivalent of =10 mg/day prednisone during the 4 weeks prior to study enrollment.
5.Patients with untreated brain metastases or carcinomatous meningitis are excluded. However, patients who have stable CNS metastases off corticosteroids, and who are at least 4 weeks from the time of appropriate directed local therapy for CNS disease are eligible for protocol enrollment.
6.Patient is unable to take and/or tolerate oral medications on a continuous basis.
7.Patient has human immunodeficiency virus (HIV) infection or HIV-related malignancy.
8.Patient has active hepatitis A, B or C infection.
9.Patient is pregnant or breast-feeding.
10.Patient has a known allergy or hypersensitivity to any component of vorinostat or carboplatin.
11.Patient has a history of gastrointestinal surgery or other procedure that may in the opinion of the investigator, interfere with the absorption or intake of study drugs.
12.Patient has uncontrolled concurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric or social conditions that may interfere with patient compliance.
13. Patient has preexisting Grade 2 or higher neuropathy.
14.Patient has a history of prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician.
15. Patient is eligible for treatment with bevacizumab in combination with paclitaxel plus carboplatin and for the given patient, bevacizumab is available and treatment with bevacizumab in combination with paclitaxel plus carboplatin is considered to be the preferred treatment Patients will be defined as eligible for treatment with bevacizumab based on the following features:
- Newly-diagnosed Stage IIIB or Stage IV NSCLC for which they have not received prior chemotherapy
- ECOG performance status of 0 or 1
- Non-squamous cell histology
- No radiation therapy within 21 days prior to randomization
- Adequate organ (hematologic, hepatic, renal) function including urinary protein excretion. For urinary protein excretion, a urine dipstick at baseline of 0 or trace is acceptable. For patients with urine dipstick results of > 1, a 24-hour urine collection must be performed and must d
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method